Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Biotech Onyx Pharmaceuticals
So what: Based on the strong phase II data, in which about one-third of patients responded to the drug for more than eight months, Onyx might be able to market its treatment much earlier than expected. Being able to access the $16 billion hematologic cancer market would obviously be a big deal for the relatively small Onyx, so it's no surprise that investors are loudly applauding the news.
Now what: Onyx's growth prospects are certainly worth looking into. While it will have to butt heads with the likes of Celgene
Interested in more info on Onyx? Add it to your watchlist.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Johnson & Johnson is a Motley Fool Income Investor pick. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson, and the Fool owns shares of it. Try any of our Foolish newsletter services free for 30 days.
True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community. The Fool's disclosure policy always gets a perfect score.